BLU-554 is primarily used in the field of oncology, specifically targeting hepatocellular carcinoma (HCC), which is the most common type of liver cancer. It functions as a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), a receptor often implicated in the progression of HCC. By inhibiting FGFR4, BLU-554 aims to disrupt the signaling pathways that promote tumor growth and survival, offering a potential therapeutic strategy for patients with this aggressive form of cancer. Its development represents a targeted approach to treatment, particularly for patients whose tumors exhibit FGFR4 pathway activation, providing a more personalized and effective treatment option compared to traditional chemotherapy. Clinical trials have been conducted to evaluate its efficacy and safety, with a focus on its ability to shrink tumors and improve patient outcomes in advanced HCC cases.